MBX Biosciences, Inc. (MBX)
Nasdaq · Healthcare · Biotechnology
$58.54+0.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.8B
- 52-week range
- $12.94 – $72.64
- 52-week change
- +259.84%
- EPS (trailing)
- −$2.37
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$87.0M
- Diluted EPS
- −$2.38
- Free cash flow
- −$81.9M
From the company’s annual report on SEC EDGAR.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Headquarters: Carmel, United States · 63 employees · mbxbio.com